Participant flow

Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized With NFKB2 Rearrangement · Source last updated 2025-06-26

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   MUTATED NFKB2 REARRANGEMENT: Patients receive ixazomib and dexamethasone as in arm A. Dexamethasone: Given PO Ixazomib: Given PO

   id

   FG000

   title

   Arm B (Ixazomib and Dexamethasone)

2. description

   MUTATED NFKB2 REARRANGEMENT: Patients receive ixazomib and dexamethasone as in arm A and lenalidomide PO daily on days 1-21. Dexamethasone: Given PO Ixazomib: Given PO Lenalidomide: Given PO

   id

   FG001

   title

   Arm C (Ixazomib, Dexamethasone, Lenalidomide)

3. description

   UNMUTATED NFKB2 REARRANGEMENT: Patients receive ixazomib and dexamethasone. Dexamethasone: Given PO Ixazomib: Given PO

   id

   FG002

   title

   Arm A (Ixazomib and Dexamethasone)

periods

1. milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         22

      2. group Id

         FG001

         num Subjects

         21

      3. group Id

         FG002

         num Subjects

         27

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         22

      2. group Id

         FG001

         num Subjects

         21

      3. group Id

         FG002

         num Subjects

         27

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         0

      2. group Id

         FG001

         num Subjects

         0

      3. group Id

         FG002

         num Subjects

         0

      type

      NOT COMPLETED

   title

   Overall Study

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice